BioCentury | Jul 18, 2016
Clinical News

ALXN1007: Interim Phase IIa data

...tract in an open-label, U.S. and French Phase IIa trial showed that once-weekly 10 mg/kg ALXN1007...
...at day 180 was 69.2%. The trial is also evaluating once- and twice-weekly 20 mg/kg ALXN1007...
...at the European Hematology Association meeting in Copenhagen. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Cheshire, Conn. Product: ALXN1007...
BioCentury | Jul 18, 2016
Clinical News

ALXN1007: Interim Phase IIa data

...tract in an open-label, U.S. and French Phase IIa trial showed that once-weekly 10 mg/kg ALXN1007...
...at day 180 was 69.2%. The trial is also evaluating once- and twice-weekly 20 mg/kg ALXN1007...
...at the European Hematology Association meeting in Copenhagen. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Cheshire, Conn. Product: ALXN1007...
BioCentury | May 18, 2015
Strategy

Alexion executes

...delayed graft function, plus one Phase II and two Phase I programs developed in house. ALXN1007...
...deficiency Sept. 8 PDUFA date; MAA action 2H15 Proposed acq of Synageva BioPharma Corp. (NASDAQ:GEVA) ALXN1007...
BioCentury | Feb 20, 2012
Clinical News

ALXN1007: Phase I started

...mg/kg IV ALXN1007 in about 56 healthy volunteers. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Cheshire, Conn. Product: ALXN1007...
Items per page:
1 - 4 of 4